Farydak
Author: Dominique Fontanilla
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Farydak (panobinostat; Novartis) is an orally available histone deacetylase (HDAC) inhibitor. Inhibition of HDAC leads to relaxed chromatin and increased transcription, causing accumulation of proteins and cell cycle arrest or apoptosis. In preclinical development for multiple myeloma (MM), Farydak was able to overcome resistance to traditional drugs like dexamethasone and melphalan. The drug also demonstrated the ability to enhance the efficacy of some established MM drugs, including Velcade (bortezomib; Takeda/Johnson & Johnson). Early-stage development suggests that Farydak has very little effect as a monotherapy.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Farydak : Multiple myeloma
LIST OF FIGURES
12 Figure 1: Farydak for multiple myeloma – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Farydak for multiple myeloma
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Farydak for multiple myeloma
16 Figure 4: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
6 Table 1: Farydak drug profile
7 Table 2: Farydak pivotal trial data in multiple myeloma
9 Table 3: Farydak early-phase trial data in multiple myeloma
11 Table 4: Farydak Phase II trial in multiple myeloma
17 Table 5: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
19 Table 6: Patients treated with Farydak across the US, Japan, and five major EU markets, by country, 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Oncology: Liquid Biopsy Products 
Sign up to the